PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals
February 23, 2021 07:00 ET
|
Newscope Capital Corporation
TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
PharmaTher Announces Sale of Psilocybin Program
February 17, 2021 09:02 ET
|
Newscope Capital Corporation
TORONTO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher” or the “Company”), is a...
PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson’s Disease
February 04, 2021 08:00 ET
|
Newscope Capital Corporation
TORONTO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine
February 01, 2021 07:59 ET
|
Newscope Capital Corporation
TORONTO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders
January 19, 2021 07:34 ET
|
Newscope Capital Corporation
TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
PharmaTher Approved to Trade on the OTCQB Venture Market
January 13, 2021 08:30 ET
|
Newscope Capital Corporation
TORONTO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF) (the "Company"), who through its wholly-owned subsidiary, PharmaTher Inc., is a specialty life...
PharmaTher Announces Application for OTCQB Listing
December 30, 2020 08:00 ET
|
Newscope Capital Corporation
TORONTO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) (the “Company”), who through its wholly owned subsidiary, PharmaTher Inc., is a specialty life...
PharmaTher Signs LOI to Sell Psilocybin Program to Revive Therapeutics
December 21, 2020 07:59 ET
|
Newscope Capital Corporation
TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty...
PharmaTher Files U.S. Patent for Novel Combinations of Psilocybin and FDA Approved Drugs to Treat Neurological Disorders
December 15, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty...
PharmaTher Granted Pre-IND Meeting with the FDA for Ketamine in Parkinson’s Disease
December 10, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty...